Cardiol Therapeutics Inc. has secured $11,000,000 in investment capital from investors. The clinical-stage life sciences company is dedicated to the research and development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. This significant funding round is expected to accelerate the advancement of its key therapeutic candidates.
The company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is currently in clinical development following Investigational New Drug Application authorization from the US Food and Drug Administration (FDA). CardiolRx™ is being evaluated in the MAVERIC Program for recurrent pericarditis, which includes the Phase II MAvERIC-Pilot study and the Phase III MAVERIC trial, and in the ARCHER trial, a Phase II study for acute myocarditis. The US FDA has also granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis. The drug candidate operates by inhibiting the inflammasome pathway, a cellular process recognized for its role in the progression of inflammation and fibrosis associated with various heart conditions.
This fresh infusion of capital will be strategically allocated to further support the ongoing clinical trials, specifically the MAVERIC and ARCHER programs, as Cardiol seeks to address critical unmet medical needs in heart disease. Additionally, the funding will contribute to the continued development of CRD-38, a novel subcutaneously administered drug formulation targeting heart failure, a major global health challenge.
The securing of these funds underscores investor confidence in Cardiol Therapeutics' pipeline and its strategic direction. The company plans to leverage this investment to enhance its research capabilities, expand its clinical development efforts, and move closer to potentially bringing innovative therapies to patients suffering from serious cardiovascular conditions. This funding is crucial for enabling Cardiol to pursue its growth initiatives and advance its mission to develop treatments for heart disease.
